Publications

  1. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG*, Kim CH*, Young TS*. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68.

  2. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG*, Young TS*, Kim CH*, Cao Y. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8.

  3. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Cao Y, Axup JY, Ma JS, Wang RE, Choi S, Tardif V, Lim RK, Pugh HM, Lawson BR, Welzel G, Kazane SA, Sun Y, Tian F, Srinagesh S, Javahishvili T, Schultz PG*, Kim CH*. Angew. Chem. Int. Ed. Engl. 2015 Jun 8;54(24):7022-7.

  4. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. Ramadoss NS, Schulman AD, Choi SH, Rodgers DT, Kazane SA, Kim CH, Lawson BR, Young TS. J. Am. Chem. Soc. 2015 Apr 29;137(16):5288-91.

  5. An immunosuppressive antibody-drug conjugate. Wang RE, Liu T, Wang Y, Cao Y, Du J, Luo X, Deshmukh V, Kim CH, Lawson BR, Tremblay MS, Young TS, Kazane SA, Wang F, Schultz PG. J. Am. Chem. Soc. 2015 Mar 11;137(9):3229-32.

  6. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, Gonzalez J, Schultz PG*, Young TS*, Kim CH*. J. Am. Chem. Soc. 2015 Mar 4;137(8):2832-5.

  7. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Lu H, Zhou Q, Deshmukh V, Phull H, Ma J, Tardif V, Naik RR, Bouvard C, Zhang Y, Choi S, Lawson BR, Zhu S, Kim CH*, Schultz PG*. Angew. Chem. Int. Ed. Engl. 2014 Sep 8;53(37):9841-5.

  8. Therapeutic applications of an expanded genetic code. Sun SB, Schutlz PG*, Kim CH*. ChemBioChem, 2014, AUG 18;15(12):1721-9.

  9. A genetically encoded aza-Michael acceptor for covalent crosslinking of protein-receptor complexes. Furman JL, Kang M, Choi S, Cao Y, Wold ED, Sun SB, Smider VV, Schultz PG*, Kim CH*. J. Am. Chem. Soc. 2014 Jun 11;136(23):8411-7

  10. Evolution of iron(II)-finger peptides by using a bipyridyl amino acid. Kang M, Light K, Ai HW, Shen W, Kim CH, Chen PR, Lee HS, Solomon EI, Schultz PG. Chembiochem. 2014 Apr 14;15(6):822-5

  11. Bispecific small molecule-antibody conjugate targeting prostate cancerKim CH*, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG*.Proc. Natl. Acad. Sci. U S A. 2013 Oct 29;110(44):17796-801

  12. Recruiting cytotoxic T cells to folate-receptor-positive cancer cells. Kularatne SA, Deshmukh V, Gymnopoulos M, Biroc SL, Xia J, Srinagesh S, Sun Y, Zou N, Shimazu M, Pinkstaff J, Ensari S, Knudsen N, Manibusan A, Axup JY, Kim CH, Smider VV, Javahishvili T, Schultz PG. Angew. Chem. Int. Ed. Engl. 2013 Nov 11;52(46):12101-4

  13. Protein Conjugation with Genetically Encoded Unnatural Amino AcidsKim CH., Axup JY, Schultz PG. Current Opinion in Chemical Biology 2013 Jun;17(3):412-9

  14. Identification of metal ion binding peptides containing unnatural amino acids by phage display. Day, JW, Kim CH., Smider, VV., Schultz, PG. Bioorg. Med. Chem. Lett. 2013 23(9):2598-600.

  15. Self-assembled antibody multimers through peptide nucleic acid conjugation. Kazane SA, Axup JY, Kim CH, Ciobanu M, Wold ED, Barluenga S, Hutchins BA, Schultz PG, Winssinger N, Smider VV. J. Am. Chem. Soc. 2013 Jan 9;135(1):340-6.

  16. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG. Proc. Natl. Acad. Sci. U S A. 2012 Oct 2;109(40):16101-6.

  17. Site-Specific Incorporation of ε-N-Crotonyllysine into HistonesKim CH, Kang M, Kim HJ, Chatterjee A, Schultz PG. Angew. Chem. Int. Ed. Engl. 2012 Jul 16;51(29):7246-9

  18. Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino AcidsKim CH, Axup JY, Dubrovska A, Kazane SA, Hutchins BA, Wold ED, Smider VV, Schultz PG. J. Am. Chem. Soc. 2012 20;134(24):9918-21.

  19. A chemically induced vaccine strategy for prostate cancer. Dubrovska A†, Kim CH†, Elliott J, Shen W, Kuo TH, Koo DI, Li C, Tuntland T, Chang J, Groessl T, Wu X, Gorney V, Ramirez-Montagut T, Spiegel DA, Cho CY, Schultz PG. ACS Chem. Biol. 2011 18;6(11):1223-31. († co-first author)

  20. 7-Phenylplatensimycin and 11-methyl-7-phenylplatensimycin: more potent analogs of platensimycin. Jang KP, Kim CH, Na SW, Jang DS, Kim H, Kang H, Lee E. Bioorg. Med. Chem. Lett. 2010 1;20(7):2156-8.

  21. Isoplatensimycin: Synthesis and biological evaluation. Jang KP, Kim CH, Na SW, Kim H, Kang H, Lee E. Bioorg. Med. Chem. Lett. 2009 15;19(16):4601-2.

  22. Stereoselective synthesis of (-)-amphidinolide EKim CH, An HJ, Shin WK, Yu W, Woo SK, Jung SK, Lee E. Chem. Asian J. 2008 1;3(8-9):1523-34.

  23. A carbonyl ylide cycloaddition approach to platensimycinKim CH, Jang KP, Choi SY, Chung YK, Lee E. Angew. Chem. Int. Ed. Engl. 2008;47(21):4009-11.

  24. Total synthesis of (-)-amphidinolide EKim CH, An HJ, Shin WK, Yu W, Woo SK, Jung SK, Lee E. Angew. Chem. Int. Ed. Engl. 2006, 45(47):8019-21

Advertisements